Sodium phosphate dibasic 2.875g/500ml / Monopotassium phosphate 647.5mg/500ml (potassium 9.5mmol/500ml) infusion 500ml polyethylene bottles
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Sodium phosphate dibasic + Monopotassium phosphate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Sodium phosphate dibasic + Monopotassium phosphate on the MHRA register
Polyfusor phosphates infusion 500ml bottles
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 9 studies.
1959–2026
Showing all 9 studies, sorted by most relevant.
L. Berg, D. Rose
Archives of biochemistry and biophysics, 1959
- Anions
- Freezing
- Phosphates
M. Rodehutscord
The Journal of nutrition, 1996
- Calcium
- Food, Fortified
- Magnesium
A. Estévez, Yomna K. Abdallah
Processes, 2024
Mineralized materials are gaining increased interest recently in a number of fields, especially in bone tissue engineering as bone replacement materials as well as in the architecture-built environment as structural building materials. Until the moment, there has not been a unified sustainable approach that addresses this multi-scale application objective by developing a self-mineralized material with minimum consumption of materials and processes. Thus, in the current study, a hydrogel developed from sodium alginate, gelatine, and calcium phosphate dibasic (CPDB) was optimized in terms of rheological properties and mineralization capacity through the formation of hydroxyapatite crystals. The hydrogel composition process adopted a three-stage, thermally induced chemical cross-linking to achieve a stable and enhanced hydrogel. The 6% CPDB-modified SA–gelatine hydrogel achieved the best rheological properties in terms of elasticity and hardness. Different concentrations of epigallocatechin gallate were tested as well as a rheological enhancer to optimize the hydrogel and to boost its anti-microbial properties. However, the results from the addition of EPGCG were not considered significant; thus, the 6% CPDB-modified SA–gelatine hydrogel was further tested for mineralization by incubation in various media, without and with cells, for 7 and 14 days, respectively, using scanning electron microscopy. The results revealed significantly enhanced mineralization of the hydrogel by forming hydroxyapatite platelets of the air-incubated hydrogel (without cells) in non-sterile conditions, exhibiting antimicrobial properties as well. Similarly, the air-incubated bioink with osteosarcoma SaOs-2 cells exhibited dense mineralized topology with hydroxyapatite crystals in the form of faceted spheres. Finally, the FBS-incubated hydrogel and FBS-incubated bioink, incubated for 7 and 14 days, respectively, exhibited less densely mineralized topology and less distribution of the hydroxyapatite crystals. The degradation rate of the hydrogel and bioink incubated in FBS after 14 days was determined by the increase in dimensions of the 3D-printed samples, which was between 5 to 20%, with increase in the bioink samples dimensions in comparison to their dimensions post cross-linking. Meanwhile, after 14 days, the hydrogel and bioink samples incubated in air exhibited shrinkage: a 2% decrease in the dimensions of the 3D-printed samples in comparison to their dimensions post cross-linking. The results prove the capacity of the developed hydrogel in achieving mineralized material with anti-microbial properties and a slow-to-moderate degradation rate for application in bone tissue engineering as well as in the built environment as a structural material using a sustainable approach.
Abstract licence: CC BY
Abdallah NA, Fathy ME, Tolba MM, et al.
2023
- COVID-19
- Ambroxol
- Common Cold
An optimization approach based on full factorial design was employed for developing an HPLC-UV method for simultaneous determination of a quaternary mixture used for the treatment of symptoms related to common cold and COVID-19. The quaternary mixture is composed of paracetamol, levocetirizine dihydrochloride, phenylephrine hydrochloride and ambroxol hydrochloride. The developed technique is a green, fast and simple method that uses isocratic elution of mobile phase consisting of 20:5:75 (v/v) of ethanol: acetonitrile: 2.5 mM heptane-1-sulphonic acid sodium salt at pH 6.5 [Formula: see text] 0.02. The chromatographic separation was carried out using Hypersil BDS Cyano LC Column (250 × 4.6 mm, 5 μm) with 230 nm UV detection and 1.0 mL/min. flow rate. Avoiding the routine methodology and resorting to the modern technology-represented in the usage of experimental design-allows rapid determination of the four drugs using the optimum quantity of chemicals to avoid any waste of resources. The quaternary mixture was eluted in less than 9 min., where retention times of paracetamol, levocetirizine dihydrochloride, phenylephrine hydrochloride and ambroxol hydrochloride were found to be 2.2, 3.8, 6.6 and 8.8 min., respectively. The calibration graphs of the four drugs were linear over concentration ranges of 50.0-500.0, 0.5-20.0, 0.5-20.0 and 0.5-100.0 µg/mL for paracetamol, levocetirizine dihydrochloride, phenylephrine hydrochloride and ambroxol hydrochloride, respectively with correlation coefficients higher than 0.999. The method is accurate with mean recoveries between 99.87 and 100.04%, precise, as %RSD for the intraday and interday precision were between 0.61 and 1.64% and very sensitive with limit of detections (LOD)'s between 29 and 147 ng/mL and limit of quantification (LOQ)'s between 95 and 485 ng/mL. The proposed method was successfully applied for the analysis of the four drugs either in raw materials or in prepared tablet with the least amount of chemicals within short time. It is also validated following International Conference on Harmonization Guidelines. The proposed method was found to be green according to the most common greenness assessment tools; NEMI, GAPI, Analytical Eco-Scale and AGREE methods. The advantages of the proposed method qualify it for routine analysis of the studied drugs either in single or co-formulated dosage form in quality control labs.
Abstract licence: CC BY
Lydia Uko, H. Noby, Abdelrahman Zkria, et al.
TECHNOLOGIES AND MATERIALS FOR RENEWABLE ENERGY, ENVIRONMENT, AND SUSTAINABILITY: TMREES23Fr, 2023
M.A. Shaymardanova, K. Mirzakulov, G. Melikulova, et al.
Chemical Problems, 2023
Tugba Turnaoglu, Navin Kumar, J. Hirschey, et al.
ASME 2023 17th International Conference on Energy Sustainability, 2023
Chávez-Herrera D, Rangel-Villanueva E, Salazar-Hernández M, et al.
2025
- Body Fluids
- Calcium Phosphates
- Biocompatible Materials
Calcium phosphate (CaP) materials are biocompatible and non-toxic to the body. However, they lack biointegration, exhibit a low resorption rate and can cause fibrous encapsulation throughout the implant material. A promising approach for dental or orthopedic regeneration is the use of dicalcium phosphate dihydrate (DCPD) and octacalcium phosphate (OCP), as they are well-suited to bone components. From a novel perspective, these apatites can be used as drug carriers for individuals with low tolerance to common excipients. In this study, the transformation of DCPD into different morphologies in DMEM was investigated using an induced dissolution and reprecipitation reaction solution. The DCPD transformation time was observed to be morphology-dependent and can occur between 48 and 168 h. In the interaction with simulated body fluid (SBF), simulated gastric fluid (SGF) and a combination of both (BFS/SGF), a higher mass loss was observed in SGF (~80%) than in the other fluids (~35%). The structural changes presented in DCPD and OCP before and after immersion in physiological fluids were analyzed by ATR-FTIR, SEM, XRD and EDS. The obtained OCP showed low stability in SGF compared to SBF and SBF/SGF, which indicates that it may be a suitable candidate for drug delivery in the digestive tract.
Abstract licence: CC BY
Kim TK, Lee MH, Shin DM, et al.
2026
Phosphates are widely used in processed meat products because of their multifunctional technological properties, including enhancing water-holding capacity, improving myofibrillar protein solubilization, stabilizing emulsions, increasing cooking yield, and supporting oxidative stability. These functions make phosphate an essential ingredient in comminuted and whole-muscle meat systems. However, increasing consumer demand for clean-label foods, concerns about the excessive intake of highly bioavailable inorganic phosphates, and sustainability issues related to finite phosphate resources have intensified the interest in phosphate reduction strategies. This review summarizes the physicochemical characteristics and functional roles of phosphates in meat systems, and discusses their potential health implications and regulatory considerations. Furthermore, recent strategies for phosphate reduction have been critically evaluated, including ingredient-based approaches (plant fibers, modified starches, functional proteins, alkaline salts, and enzymatic systems) and processing-based technologies (high-pressure processing, ultrasound, and optimized tumbling). Although no single substitute fully replicates the multifunctional effects of phosphates, integrated or hurdle-based approaches combining multifunctional ingredients with advanced processing technologies show considerable promise. Partial replacement is generally more feasible than complete elimination, particularly for emulsified meat products. Future research should focus on elucidating protein–water interaction mechanisms, developing clean-label multifunctional systems, and validating long-term quality and consumer acceptance. Strategic phosphate reduction is technologically achievable and aligns with global trends toward healthier, sustainable, and clean-label meat products.
Abstract licence: CC BY-NC-ND
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.